COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,800 Articles (22,527 medRxiv, 8,273 bioRxiv)

Most recent first Previous |  Page 1767: Articles 17661-17670  | Next

Hospitalizations for emergency-sensitive conditions in Germany during the Covid-19 pandemic - Insights from the German-wide Helios hospital network
BOLLMANN, A., Hohenstein, S., Pellissier, V., Koenig, S., Ueberham, L., Hindricks, G., Meier-Hellmann, A., Kuhlen, R.
10.1101/2021.02.08.21250309 — Posted: 2021-02-11
Hospitalizations, resource use and outcomes of acute pulmonary embolism in Germany during the Covid-19 pandemic - Emergence of different phenotypes of thrombotic disease?
Husser, D., Hohenstein, S., Pellissier, V., Koenig, S., Ueberham, L., Hindricks, G., Meier-Hellmann, A., Kuhlen, R., BOLLMANN, A.
10.1101/2021.02.08.21250291 — Posted: 2021-02-11
Implementation of an in-house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2 N501Y variants
Bedotto, M., Fournier, P.-E., Houhamdi, L., Colson, P., Raoult, D.
10.1101/2021.02.03.21250661 — Posted: 2021-02-11
SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020
Chisolm, T., Walker, J. P., Leys, Y., Butterfield, T. R., Medley, C., Thompson, T. K., Reynolds-Campbell, G., Mulder, W. H., Campbell Mitchell, M., Anzinger, J. J.
10.1101/2021.02.08.21251367 — Posted: 2021-02-11
Association of state social distancing restrictions with nursing home COVID-19 and non-COVID-19 outcomes
Li, Y., Cheng, Z., Cai, X., Mao, Y., Temkin-Greener, H.
10.1101/2021.02.08.21251382 — Posted: 2021-02-11
Estimating real-world COVID-19 vaccine effectiveness in Israel
Aran, D.
10.1101/2021.02.05.21251139 — Posted: 2021-02-11 Discussion: Onsite
Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients
Das, S., Pearson, M., Taylor, K., Bouchet, V., Moller, G. L., Hall, T. O., Strivens, M., Tzeng, K. T. H., Gardner, S.
10.1101/2021.02.08.21250899 — Posted: 2021-02-11
How much do superspreaders matter? Epidemic dynamics in inhomogeneous populations
Kawagoe, K., Rychnovsky, M., Chang, S. Y., Huber, G., Li, L. M., Miller, J., Pnini, R., Veytsman, B., Yllanes, D.
10.1101/2021.02.08.21251386 — Posted: 2021-02-11
Country specific mutational profile of SARS-CoV-2 in pre- and post-international travel ban: Effect on vaccine efficacy
Laha, S., Chatterjee, R.
10.1101/2021.02.08.21251359 — Posted: 2021-02-11
Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report
Hernandez, M. M., Gonzalez-Reiche, A. S., Alshammary, H., Fabre, S., Khan, Z., van De Guchte, A., Obla, A., Ellis, E., Sullivan, M. J., Tan, J., Alburquerque, B., Soto, J., Wang, C.-Y., Sridhar, S. H., Wang, Y.-C., Smith, M., Sebra, R., Paniz-Mondolfi, A. E., Gitman, M. R., Nowak, M. D., Cordon-Cardo, C., Luksza, M., Krammer, F., van Bakel, H., Simon, V., Sordillo, E. M.
10.1101/2021.02.08.21251303 — Posted: 2021-02-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).